Pluristem Therapeutics, Inc. (PSTI) Announces Earnings Results
Pluristem Therapeutics, Inc. (NASDAQ:PSTI) issued its quarterly earnings data on Monday. The biotechnology company reported ($0.08) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.08), Zacks reports.
Pluristem Therapeutics (NASDAQ PSTI) opened at $1.46 on Tuesday. Pluristem Therapeutics has a 12-month low of $1.04 and a 12-month high of $2.12.
ILLEGAL ACTIVITY WARNING: “Pluristem Therapeutics, Inc. (PSTI) Announces Earnings Results” was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/11/14/pluristem-therapeutics-inc-psti-announces-earnings-results.html.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.